Stockscreener 앱 받기
33.25
0.06%
0.02
시간 외 거래:
33.08
-0.17
-0.51%
전일 마감가:
$33.23
열려 있는:
$33.48
하루 거래량:
652.63K
Relative Volume:
1.31
시가총액:
$1.06B
수익:
$780.57M
순이익/손실:
$62.87M
주가수익비율:
19.36
EPS:
1.7171
순현금흐름:
$327.58M
1주 성능:
-4.45%
1개월 성능:
-27.32%
6개월 성능:
-4.04%
1년 성능:
+10.28%
1일 변동 폭
$33.20
$33.76
1주일 범위
$32.86
$36.88
52주 변동 폭
$23.23
$50.79
Collegium Pharmaceutical Inc Stock (COLL) Company Profile
명칭
Collegium Pharmaceutical Inc
전화
781-713-3699
주소
100 TECHNOLOGY CENTER DRIVE, STOUGHTON, MA
Compare COLL vs TAK, ZTS, HLN, TEVA, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
COLL
Collegium Pharmaceutical Inc
|
33.25 | 1.06B | 780.57M | 62.87M | 327.58M | 1.7171 |
TAK
Takeda Pharmaceutical Co Adr
|
18.29 | 56.99B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
116.71 | 48.94B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.74 | 43.30B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.46 | 33.94B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
541.60 | 23.31B | 3.18B | 1.33B | 1.04B | 27.90 |
Collegium Pharmaceutical Inc Stock (COLL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-09 | 개시 | Barclays | Overweight |
| 2025-01-10 | 업그레이드 | Needham | Hold → Buy |
| 2024-07-30 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2024-06-07 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-05-10 | 다운그레이드 | Needham | Buy → Hold |
| 2024-05-10 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-01-04 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-08-25 | 재확인 | Needham | Buy |
| 2023-05-02 | 재개 | Jefferies | Buy |
| 2022-08-08 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2022-02-15 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2021-08-06 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2021-01-11 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-14 | 개시 | BWS Financial | Sell |
| 2020-05-27 | 개시 | Guggenheim | Neutral |
| 2020-02-19 | 재개 | Jefferies | Buy |
| 2019-10-30 | 재확인 | Needham | Buy |
| 2019-05-03 | 재개 | H.C. Wainwright | Buy |
| 2019-04-12 | 재개 | Janney | Buy |
| 2019-03-20 | 개시 | SunTrust | Hold |
| 2019-01-16 | 재확인 | Needham | Buy |
| 2018-03-08 | 재확인 | H.C. Wainwright | Buy |
| 2018-02-07 | 재확인 | Needham | Buy |
| 2017-12-05 | 재확인 | Needham | Buy |
| 2017-09-11 | 개시 | H.C. Wainwright | Buy |
| 2017-05-11 | 재확인 | Needham | Buy |
| 2016-09-13 | 개시 | Gabelli & Co | Buy |
| 2015-06-01 | 개시 | Jefferies | Buy |
| 2015-06-01 | 개시 | Needham | Buy |
| 2015-06-01 | 개시 | Piper Jaffray | Overweight |
모두보기
Collegium Pharmaceutical Inc 주식(COLL)의 최신 뉴스
Collegium Pharmaceutical EVP Sells Nearly 50,000 Shares Worth $2 Million - The Motley Fool
Collegium Pharmaceutical, Inc. (COLL) Discusses Acquisition of AZSTARYS to Expand ADHD Portfolio and Accelerate GrowthSlideshow (NASDAQ:COLL) 2026-03-24 - Seeking Alpha
Collegium Pharmaceutical Stock Gains Momentum After Key Debt Repayment and Strong Earnings Momentum - AD HOC NEWS
Collegium Pharmaceutical (COLL) Valuation Check After Recent Share Price Volatility - Sahm
Insider Selling: Collegium Pharmaceutical (NASDAQ:COLL) EVP Sells 13,976 Shares of Stock - MarketBeat
Dieter David, Collegium Pharmaceutical EVP, sells $488k in stock By Investing.com - Investing.com Canada
Collegium (NASDAQ: COLL) EVP trades 13,976 shares under 10b5-1 plan - Stock Titan
Collegium Pharmaceuticals: Another M&A Episode Adds To An Intriguing Case (NASDAQ:COLL) - Seeking Alpha
Collegium Pharmaceutical stock faces scrutiny amid opioid market shifts and regulatory pressures - AD HOC NEWS
Pharma M&A Roundup: Novartis to Acquire Pan-Mutant-Selective PI3Kα Inhibitor from Synnovation Therapeutics, Collegium to Acquire Azstarys from Corium Therapeutics - Pharmaceutical Executive
Azstarys (re-)born with Collegium’s ADHD buy - BioWorld MedTech
Collegium Pharmaceutical Expands ADHD Portfolio With AZSTARYS And Valuation Gap - simplywall.st
Needham & Company LLC Reiterates Buy Rating for Collegium Pharmaceutical (NASDAQ:COLL) - MarketBeat
Collegium Pharmaceutical (NASDAQ:COLL) Given Buy Rating at HC Wainwright - MarketBeat
Collegium to acquire Azstarys from Corium Therapeutics - The Pharma Letter
Collegium Pharmaceutical to Acquire AZSTARYS® for $650 Million, Expanding ADHD Portfolio and Projecting Over $50 Million Revenue in Late 2026 - Minichart
Collegium Pharmaceutical to acquire AZSTARYS for $650 million By Investing.com - Investing.com Australia
Jefferies reiterates Collegium Pharmaceutical stock Buy on ADHD deal By Investing.com - Investing.com Canada
Collegium Pharmaceutical to Acquire AZSTARYS ADHD Franchise - TipRanks
Collegium (NASDAQ: COLL) to acquire AZSTARYS in $650M ADHD expansion deal - Stock Titan
Barclays reiterates Collegium Pharmaceutical stock rating at Overweight By Investing.com - Investing.com Canada
Collegium Pharmaceutical (NASDAQ:COLL) Shares Gap UpShould You Buy? - MarketBeat
Collegium ponies up $650M to gain ADHD drug Azstarys from Corium - Fierce Pharma
Collegium Pharmaceutical to acquire Corium's ADHD drug for up to $785 million - marketscreener.com
Collegium Pharmaceutical to Buy AZSTARYS for $650M, Expanding ADHD Franchise Through 2037 - MarketBeat
Collegium Pharmaceutical to acquire AZSTARYS for $650 million - Investing.com
Collegium Pharmaceutical to Acquire Azstarys From Corium Therapeutics for $650 Million in Cash - marketscreener.com
Collegium to Acquire AZSTARYS® from Corium Therapeutics, - GlobeNewswire
Collegium to Acquire AZSTARYS® from Corium Therapeutics, Strengthening Position in ADHD and Accelerating Growth Trajectory - Sahm
Fidelity lists 13,976 COLL shares for sale (NASDAQ: COLL) - Stock Titan
Whale Trades: What are analysts price targets for Collegium Pharmaceutical Inc2026 EndofMonth & Expert Curated Trade Setup Alerts - baoquankhu1.vn
BrightSpring Health Services, Collegium Pharmaceutical, and Phibro Animal Health Shares Are Soaring, What You Need To Know - Yahoo Finance
Member Spotlight: Collegium Pharmaceutical - Massachusetts Biotechnology Council
Collegium Pharmaceutical, Inc. $COLL Position Reduced by Eventide Asset Management LLC - MarketBeat
Collegium Pharmaceutical touts record 2025, sees JORNAY PM driving 2026 growth at Barclays Miami Conference - MarketBeat
A Look At Collegium Pharmaceutical (COLL) Valuation After Recent Share Price Pressure - Yahoo Finance
3 Healthcare Stocks Walking a Fine Line - The Globe and Mail
Insider Sell: David Dieter Sells Shares of Collegium Pharmaceuti - GuruFocus
Risk Recap: What is the dividend yield of Collegium Pharmaceutical IncIndex Update & Weekly Setup with ROI Potential - baoquankhu1.vn
Collegium (NASDAQ: COLL) EVP sells 6,224 shares under 10b5-1 plan - Stock Titan
Collegium Pharmaceutical at Barclays Conference: Strategic Growth and Challenges By Investing.com - Investing.com Canada
WINTON GROUP Ltd Purchases Shares of 65,345 Collegium Pharmaceutical, Inc. $COLL - MarketBeat
Victory Capital Management Inc. Cuts Stock Position in Collegium Pharmaceutical, Inc. $COLL - MarketBeat
Collegium Pharmaceutical (COLL) Surged Following Record Quarterly Results - Insider Monkey
Assessing Collegium Pharmaceutical (COLL) Valuation After Recent Share Price Weakness - simplywall.st
Jefferies Financial Group Inc. Takes $4.43 Million Position in Collegium Pharmaceutical, Inc. $COLL - MarketBeat
[144] COLLEGIUM PHARMACEUTICAL, INC SEC Filing - Stock Titan
Market Catalysts: Can Collegium Pharmaceutical Inc be the next market leaderMarket Movers & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Collegium Pharmaceutical, Inc. (COLL) gains momentum on Jornay PM, Truist highlights robust pain portfolio - MSN
Dow Update: Will Collegium Pharmaceutical Inc benefit from green energy policiesTrade Volume Report & Smart Money Movement Alerts - baoquankhu1.vn
(COLL) Volatility Zones as Tactical Triggers - Stock Traders Daily
Collegium Pharmaceutical Inc (COLL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.12%
1.13%
자본화:
|
볼륨(24시간):